FDA Approves Breakthrough Pancreatic Cancer Drug – An Oncologist Explains How Daraxonrasib Nearly Doubles Survival
The FDA’s approval of daraxonrasib marks a significant development in pancreatic cancer treatment, with clinical trial results suggesting the drug can substantially extend survival for some patients.
← Back to stories
National2 articles from 2 sources across the spectrum· Updated 7d ago
1 across the spectrum · tap a section to jump
Left
1 viewpointFDA Approves Breakthrough Pancreatic Cancer Drug – An Oncologist Explains How Daraxonrasib Nearly Doubles Survival
Center
0 viewpointsNo Center coverage yet.
A blind spot on this side of the story.
Right
0 viewpointsNo Right coverage yet.
A blind spot on this side of the story.
Other outlets
International, entertainment and tech outlets, by their rating. Not counted in the bar above. How we count coverage
Left
1 articleCenter
0 articlesNone
Right
0 articlesNone